Loading...
XSHG603229
Market cap1.01bUSD
Jan 14, Last price  
8.96CNY
1D
0.90%
1Q
13.13%
IPO
138.30%
Name

Zhejiang Ausun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603229 chart
P/E
29.30
P/S
9.11
EPS
0.31
Div Yield, %
0.77%
Shrs. gr., 5y
2.08%
Rev. gr., 5y
27.35%
Revenues
817m
+6.83%
58,930,963120,948,643201,417,276262,666,048198,841,958240,188,298243,885,062307,914,615409,249,350569,698,344764,547,389816,765,083
Net income
254m
+7.87%
2,293,87215,552,69921,501,01360,865,08857,328,09453,011,51743,864,09056,386,59286,836,031145,930,186235,375,827253,901,967
CFO
222m
+84.00%
-1,138,30015,729,90021,450,35653,626,06993,207,58846,784,77711,503,53687,729,755138,470,268173,900,860120,567,033221,847,783
Dividend
Jul 12, 20240.1806 CNY/sh
Earnings
May 20, 2025

Profile

Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it is involved in the processing, and research and development business. The company was founded in 2010 is based in Linhai, China.
URL
https://www.ausunpharm.com/
IPO date
May 09, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
816,765
6.83%
764,547
34.20%
Cost of revenue
515,453
498,399
Unusual Expense (Income)
NOPBT
301,312
266,148
NOPBT Margin
36.89%
34.81%
Operating Taxes
36,860
20,483
Tax Rate
12.23%
7.70%
NOPAT
264,452
245,665
Net income
253,902
7.87%
235,376
61.29%
Dividends
(57,449)
(29,279)
Dividend yield
0.73%
0.31%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
300,260
169,279
Long-term debt
4,078
72,744
Deferred revenue
34,914
23,507
Other long-term liabilities
1
2
Net debt
(887,258)
(416,972)
Cash flow
Cash from operating activities
221,848
120,567
CAPEX
(163,470)
Cash from investing activities
(175,470)
Cash from financing activities
469,925
94,917
FCF
70,955
(103,822)
Balance
Cash
1,124,230
612,873
Long term investments
67,367
46,123
Excess cash
1,150,758
620,768
Stockholders' equity
1,359,365
1,066,419
Invested Capital
1,328,031
1,102,074
ROIC
21.76%
27.66%
ROCE
12.15%
15.34%
EV
Common stock shares outstanding
593,069
562,613
Price
13.21
-22.29%
17.00
-8.50%
Market cap
7,834,447
-18.09%
9,564,424
-8.21%
EV
6,947,188
9,147,451
EBITDA
341,905
300,626
EV/EBITDA
20.32
30.43
Interest
8,272
6,107
Interest/NOPBT
2.75%
2.29%